Drug Trial Radar · NCT07916259
The Study of Brave-LC LDN Treatment Trial
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,300
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Dec 31, 2028
Study completion Jan 1, 2029
Sponsor
- Sponsor type
- NIH
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of a 16-week course of low-dose naltrexone (LDN) in approximately 1,300 participants aged 6 to 25 years with fatigue associated with Long COVID. Participants will be enrolled across three age cohorts (6-11, 12-17, and 18-25 years) and randomized 1:1 to receive LDN capsules or matching placebo capsules. LDN will be initiated at 1.5 mg daily and titrated weekly to a maximum tolerated dose of up to 4.5 mg daily. Randomization will be stratified by age cohort, and participants will also be randomized to a pharmacokinetic (PK) sampling window. Primary objective is to compare the change in fatigue severity from baseline to 16 weeks between participants aged 6 to 25 years with Long COVID randomized to a 16-week course of LDN or placebo.
Conditions
- Post-acute COVID-19 Syndrome
Interventions
naltrexoneDrug
Opioid receptor antagonist used to treat opioid and alcohol use disorders in adults. Formulated as naltrexone hydrochloride, a white, crystalline compound freely soluble in water.
PlaceboOther
Matching placebo capsule that is visually identical to the active study product and is administered orally once daily according to the same dosing schedule and titration scheme for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Pediatric Quality of Life - Multidimensional Fatigue Scale (PedsQL-MFS) total score.Time frame: Baseline to 16 weeks after randomization
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Children's of Alabama Child Health Research Unit (CHRU)
Birmingham, Alabama
Exalt Clinical Research Inc.
Chula Vista, California
Denver Health
Denver, Colorado
University of Florida Health
Gainesville, Florida
Rush University Medical Center
Chicago, Illinois
Kennedy Krieger Institute
Baltimore, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Dartmouth Health
Lebanon, New Hampshire
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
NYU Langone Hospital - Brooklyn
Brooklyn, New York
Columbia University
New York, New York
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.